FDA Orders New GLP-1 Risk Warnings Over Vision Loss
Ruling or order from the legal press · reported by 3 publishers
Headline as published by Law360 Product Liability on Nov 9, 2026; collected by the wire Nov 9, 2026, 6:30 PM ET.
Coverage
Named in this story
- AgencyU.S. Food and Drug AdministrationMatched on
FDA
,Food and Drug Administration
- FirmLaw360Linked on a hard id: the report is published on the firm’s own domain (
law360.com
). - MDLMDL 3094 · GLP-1 Receptor AgonistsMatched on
GLP-1
- MDLMDL 3163 · GLP-1 Vision Loss (NAION)Matched on
NAION
Topics
- Mass torts and MDLsMatched on
GLP-1
- Product liabilityFrom the publisher’s section: no phrase in the text matched, so the tag comes from where Law360 Product Liability filed it.
- Drugs and medical devicesMatched on
Drug Labels
- Lawsuits and filingsMatched on
lawsuits
Explore the named firms, organizations and MDL dockets above. Sources and method
MDL No. 3094
GLP-1 Receptor Agonists
IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
- Transferee judge
- Karen S. Marston
- Court
- Eastern District of Pennsylvania
- Actions pending
- 4,025
Per the JPML pending-dockets report of October 1, 2026.
MDL No. 3163
GLP-1 Vision Loss (NAION)
IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation
- Transferee judge
- Karen S. Marston
- Court
- Eastern District of Pennsylvania
- Actions pending
- 247
Per the JPML pending-dockets report of October 1, 2026.